Accelerating global innovation to address antibacterial resistance: introducing CARB-X.


A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.


Outterson, Kevin; Rex, John H; Jinks, Tim; Jackson, Peter; Hallinan, John; Karp, Steve; Hung, Deborah T; Franceschi, Francois; Merkeley, Tyler; Houchens, Christopher; Dixon, Dennis M; Kurilla, Michael; Aurigemma, Rosemarie; Larsen, Joseph;


  • Anti-Bacterial Agents/ pharmacology
  • Anti-Bacterial Agents/ therapeutic use
  • Bacterial Infections/ drug therapy
  • Bacterial Infections/ microbiology
  • Biomedical Research/ economics
  • Biomedical Research/ organization & administration
  • Clinical Trials as Topic
  • Drug Resistance, Bacterial
  • Humans
  • Public-Private Sector Partnerships

External Links